The cardiovascular effects of chronic hypoestrogenism in amenorrhoeic athletes: A critical review

Sports Medicine

Volumn 34, Issue 9, 2004, Pages 601-627

  O'Donnell, Emma ^a   De Souza, Mary Jane ^a  

^a UNIVERSITY OF TORONTO   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

C REACTIVE PROTEIN; ENDOTHELIN; ESTROGEN; HIGH DENSITY LIPOPROTEIN; HOMOCYSTEINE; LOW DENSITY LIPOPROTEIN; NITRATE; NITRITE; TRIACYLGLYCEROL;

AMENORRHEA; ATHLETE; CARDIOVASCULAR EFFECT; CARDIOVASCULAR RISK; ENDOTHELIUM; EXERCISE; HEART PROTECTION; HORMONE SUBSTITUTION; HUMAN; INCIDENCE; LIPID PEROXIDATION; MENSTRUATION DISORDER; POSTMENOPAUSE; PREDICTION; REVIEW; SITTING;

ADULT; AMENORRHEA; CARDIOVASCULAR SYSTEM; CHRONIC DISEASE; ESTROGENS; EXERCISE; FEMALE; HORMONE REPLACEMENT THERAPY; HUMANS; MIDDLE AGED; SPORTS;

EID: 4344586459     PISSN: 01121642     EISSN: None     Source Type: Journal    
DOI: 10.2165/00007256-200434090-00004     Document Type: Review

References (259)

1. Frankovich RJ, Lebrun CM. The athletic woman: menstrual cycle, contraception, and performance. Clin Sports Med 2000; 19 (2): 251-71
2. Otis CL, Drinkwater B, Johnson M, et al. American College of Sports Medicine position stand: the female athlete triad. Med Sci Sports Exerc 1997 May; 29 (5): i-ix
3. Williams NI, Helmreich DL, Parfitt DB, et al. Evidence for a causal role of low energy availability in the induction of menstrual cycle disturbances during strenuous exercise training. J Clin Endocrinol Metab 2001; 86 (11): 5184-93
4. Loucks AB, Verdun M, Heath ME. Low energy availability, not stress of exercise, alters LH pulsatility in exercising women. J Appl Physiol 1998; 84 (1): 37-46
5. Loucks AB, Heath EM. Induction of low-T3 syndrome in exercising women occurs at a threshold of energy availability. Am J Physiol 1994; 266: R817-23
6. Wade GN, Schneider JE, Li HY. Control of fertility by metabolic cues. Am J Physiol 1996 Jan; 270 (1): E1-19
7. Fruth SJ, Worrell TW. Factors associated with menstrual irregularities and decreased bone mineral density in female athletes. J Orthop Sports Phys Ther 1995 Jul; 22 (1): 26-38
8. Drinkwater BL. Exercise and bones: lessons learned from female athletes. Am J Sports Med 1996; 24 (6 Suppl.): S33-5
9. Keen AD, Drinkwater BL. Irreversible bone loss in former amenorrheic athletes. Osteoporos Int 1997; 7 (4): 311-5
10. Yeager KK, Agostini R, Nattiv A, et al. The female athlete triad: disordered eating, amenorrhea, osteoporosis. Med Sci Sports Exerc 1993 Jul; 25 (7): 775-7
11. Zeni Hoch A, Dempsey RL, Carrera GF, et al. Is there an association between athletic amenorrhea and endothelial cell dysfunction? Med Sci Sports Exerc 2003 Mar; 35 (3): 377-83
12. Stevenson J, Crook D, Godsland I. Influence of age and menopause on serum lipids and lipoproteins in healthy women. Atherosclerosis 1993; 98: 83-90
13. Ridker PM, Hennekens CH, Buring JE, et al. C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N Engl J Med 2000; 342 (12): 836-43
14. Lieberman EH, Gerhard MD, Uehata A, et al. Estrogen improves endothelium-dependent, flow-mediated vasodilation in postmenopausal women. Ann Intern Med 1994 Dec; 121: 936-41
15. Rosenson RS, Tangney CC, Mosca LJ. Hormone replacement therapy improves cardiovascular risk by lowering plasma viscosity in postmenopausal women. Arterioscler Thromb Vasc Biol 1998 Dec; 18 (12): 1902-5
16. Moreau KL, Donate AJ, Tanaka H, et al. Basal leg blood flow in healthy women is related to age and hormone replacement therapy status. J Physiol 2003 Feb 15; 547 (Pt 1): 309-16
17. Mijatovic V, Kenemans P, Jakobs C, et al. A randomized controlled study of the effects of 17beta-estradiol-dydrogesterone on plasma homocysteine in postmenopausal women. Obstet Gynecol 1998 Mar; 91 (3): 432-6
18. Yildirir A, Aybar F, Tokgozoglu L, et al. Effects of hormone replacement therapy on plasma homocysteine and C-reactive protein levels. Gynecol Obstet Invest 2002; 53 (1): 54-8
19. Yen CH, Hsieh CC, Chou SY, et al. 17Beta-estradiol inhibits oxidized low density lipoprotein-induced generation of reactive oxygen species in endothelial cells. Life Sci 2001 Dec 14; 70 (4): 403-13
20. Wenger NK. Menopausal hormone therapy and cardiovascular protection: state of the data 2003. J Am Med Womens Assoc 2003 Fall; 58 (4): 236-9
21. Friday KE, Drinkwater BL, Bruemmer B, et al. Elevated plasma low-density lipoprotein and high-density lipoprotein cholesterol levels in amenorrheic athletes: effects of endogenous hormone status and nutrient intake. J Clin Endocrinol Metab 1993 Dec; 77 (6): 1605-9
22. Stacey E, Korkia P, Hukkanen MV, et al. Decreased nitric oxide levels and bone turnover in amenorrheic athletes with spinal osteopenia. J Clin Endocrinol Metab 1998 Sep; 83 (9): 3056-61
23. Ayres S, Baer J, Subbiah MT, et al. Exercised-induced increase in lipid peroxidation parameters in amenorrheic female athletes. Fertil Steril 1998 Jan; 69 (1): 73-7
24. McArdle WD, Katch FI, Katch VL. Exercise physiology: energy, nutrition, and human performance. 3rd rev. ed. Philidelphia (PA): Lea and Febiger, 1991: 19
25. Bocan TM. Pleiotropic effects of HMG-CoA reductase inhibitors. Curr Opin Investig Drugs 2002 Sep; 3 (9): 1312-7
26. Dietschy JM. Dietary fatty acids and the regulation of plasma low density lipoprotein cholesterol concentrations. J Nutr 1998 Feb; 128 (2 Suppl.): 444S-8S
27. NCEP Group. Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). JAMA 2001 May 16; 285 (19): 2486-97
28. Irons BK, Snella KA, McCall K, et al. Update on the management of dyslipidemia. Am J Health Syst Pharm 2002 Sep 1; 59 (17): 1615-25
29. Stone NJ. Secondary causes of hyperlipidemia. Med Clin North Am 1994; 78: 117-41
30. Chait A, Brunzell JD. Acquired hyperlipidemia (secondary dyslipoproteinemias). Endocrinol Metab Clin North Am 1990; 19: 259-78
31. Ineck BA, Ng TM. Effects of subclinical hypothyroidism and its treatment on serum lipids. Ann Pharmacother 2003 May; 37 (5): 725-30.
32. Urabe M, Yamamoto T, Kashiwagi T, et al. Effect of estrogen replacement therapy on hepatic triglyceride lipase, lipoprotein lipase and lipids including apolipoprotein E in climacteric and elderly women. Endocr J 1996 Dec; 43 (6): 737-42
33. Jensen J, Nilas L, Christiansen C. Influence of menopause on serum lipids and lipoproteins. Maturitas 1990 Nov; 12 (4); 321-31
34. Haddock BL, Marshak HP, Mason JJ, et al. The effect of hormone replacement therapy and exercise on cardiovascular disease risk factors in postmenopausal women. Sports Med 2000 Jan; 29 (1): 39-49
35. Akahoshi M, Soda M, Nakashima E, et al. Effects of age at menopause on serum cholesterol, body mass index, and blood pressure. Atherosclerosis 2001 May; 156 (1): 157-63
36. PEPI Group. Effects of estrogen or estrogen/progestin regimens on heart disease risk factors in postmenopausal women. The Postmenopausal Estrogen/Progestin Interventions (PEPI) Trial. The Writing Group for the PEPI Trial. JAMA 1995. Jan 18; 273 (3): 199-208
37. Farish E, Spowart K, Barnes JF, et al. Effects of postmenopausal hormone replacement therapy on lipoproteins including lipoprotein (a) and LDL subfractions. Atherosclerosis 1996 Sep 27; 126 (1): 77-84
38. Lip GY, Blann AD, Jones AF, et al. Effects of hormone-replacement therapy on hemostatic factors, lipid factors, and endothelial function in women undergoing surgical menopause: implications for prevention of atherosclerosis. Am Heart J 1997 Oct; 134 (4): 764-71
39. Jensen J, Riis BJ, Strom V, et al. Long-term effects of percutaneous estrogens and oral progesterone on serum lipoproteins in postmenopausal women. Am J Obstet Gynecol 1987 Jan; 156 (1): 66-71
40. Crook D, Cust MP, Gangar KF, et al. Comparison of transdermal and oral estrogen-progestin replacement therapy: effects on serum lipids and lipoproteins. Am J Obstet Gynecol 1992 Mar; 166 (3): 950-5
41. Hanggi W, Lippuner K, Riesen W, et al. Long-term influence of different postmenopausal hormone replacement regimens on serum lipids and lipoprotein (a): a randomised study. Br J Obstet Gynaecol 1997 Jun; 104 (6): 708-17
42. Baer JT. Lipid status in female athletes with low estrogen: applications to cardiovascular risk. Am J Health Studies 1999; 15 (1): 29-35
43. Thompson DL, Snead DB, Seip RL, et al. Serum lipid levels and steroidal hormones in women runners with irregular menses. Can J Appl Physiol 1997 Feb; 22 (1): 66-77
44. Lamon-Fava S, Fisher EC, Nelson ME, et al. Effect of exercise and menstrual cycle status on plasma lipids, low density lipoprotein particle size, and apolipoproteins. J Clin Endocrinol Metab 1989 Jan; 68 (1): 17-21
45. Manninen V, Elo MO, Frick MH, et al. Lipid alterations and decline in the incidence of coronary heart disease in the Helsinki Heart Study. JAMA 1988; 260: 641-51
46. Kaiserauer S, Snyder AC, Sleeper M, et al. Nutritional, physiological, and menstrual status of distance runners. Med Sci Sports Exerc 1989 Apr; 21 (2): 120-5
47. Marcus R, Cann C, Madvig P, et al. Menstrual function and bone mass in elite women distance runners. Ann Intern Med 1985; 102: 158-63
48. van Baal WM, Smolders RG, van der Mooren MJ, et al. Hormone replacement therapy and plasma homocysteine levels. Obstet Gynecol 1999 Oct; 94 (4): 485-91
49. Nova E, Varela P, Lopez-Vidriero I, et al. A one year follow-up study in anorexia nervosa: dietary pattern and anthropometrical evolution. Eur J Clin Nutr 2001; 55: 547-54
50. Sanchez-Muniz FJ, Marcos A, Varela P. Serum lipids and apolipoprotein B values, blood pressure and pulse rate in anorexia nervosa. Eur J Clin Nutr 1991 Jan; 45 (1): 33-6
51. Mehler PS, Lezotte D, Eckel R. Lipid levels in anorexia nervosa. Int J Eat Disord 1998 Sep; 24 (2): 217-21
52. Feillet F, Feillet-Coudray C, Bard JM, et al. Plasma cholesterol and endogenous cholesterol synthesis during refeeding in anorexia nervosa. Clin Chim Acta 2000 Apr; 294 (1-2): 45-56
53. Zak A, Vecka M, Tvrzicka E, et al. Lipid metabolism in anorexia nervosa [in Czech]. Cas Lek Cesk 2003; 142 (5): 280-4
54. Nelson ME, Fisher EC, Catsus PD, et al. Diet and bone status in amenorrheic runners. Am J Clin Nutr 1986; 43: 910-6
55. Laughlin GA, Yen SS. Nutritional and endocrine-metabolic aberrations in amenorrheic athletes. J Clin Endocrinol Metab 1996; 81: 4301-9
56. Roeters van Lennep JE, Westerveld HT, Erkelens DW, et al. Risk factors for coronary heart disease: implications of gender. Cardiovasc Res 2002 Feb 15; 53 (3): 538-49
57. Dietschy JM, Turley SD, Spady DK. Role of liver in the maintenance of cholesterol and low density lipoprotein homeostasis in different animal species, including humans. J Lipid Res 1993; 34: 1637-59
58. Dietschy JM. Theoretical considerations of what regulates low-density-lipoprotein and high-density-lipoprotein cholesterol. Am J Clin Nutr 1997; 65: 1581S-9S
59. Liscum L, Munn NJ. Intracellular cholesterol transport. Biochim Biophys Acta 1999 Apr; 1438 (1): 19-37
60. Baynes JW. Chemical modification of proteins by lipids in diabetes. Clin Chem Lab Med 2003 Sep; 41 (9): 1159-65
61. Stefanick ML, Mackey S, Sheehan M, et al. Effects of diet and exercise in men and postmenopausal women with low levels of HDL cholesterol and high levels of LDL cholesterol. N Engl J Med 1998 Jul 2; 339 (1): 12-20
62. NIH Consensus Statement. Triglyceride, high density lipoprotein, and coronary heart disease [online]. Available from URL: http://consensus.nih.gov/ cons/089/089_intro.htm [Accessed 2003 Oct 1]
63. O'Connell BJ, Genest J. High-density lipoproteins and endothelial function. Circulation 2001; 104: 1978-83
64. Barrett-Connor EL. Testosterone and risk factors for cardiovascular disease in men. Diabetes Metab 1995 Jun; 21 (3): 156-61
65. Schwertz DW, Penckofer S. Sex differences and the effects of sex hormones on hemostasis and vascular reactivity. Heart Lung 2001; 30 (6): 401-28
66. Mendelsohn ME. Mechanisms of estrogen action in the cardiovascular system. J Steroid Biochem Mol Biol 2000 Nov 30; 74 (5): 337-43
67. Karjalainen A, Heikkinen J, Savolainen MJ, et al. Mechanisms regulating LDL metabolism in subjects on peroral and transdermal estrogen replacement therapy. Arterioscler Thromb Vasc Biol 2000 Apr; 20 (4): 1101-6
68. Mendelsohn ME, Karas RH. The protective effects of estrogen on the cardiovascular system. N Engl J Med 1999; 340 (23): 1801-11
69. Muesing RA, Forman MR, Graubard BI, et al. Cyclic changes in lipoprotein and apolipoprotein levels during the menstrual cycle in healthy premenopausal women on a controlled diet. J Clin Endocrinol Metab 1996 Oct; 81 (10): 3599-603
70. Chen FP, Lee N, Soong YK, et al. Comparison of transdermal and oral estrogen-progestin replacement therapy: effects on cardiovascular risk factors. Menopause 2001 Sep-Oct; 8 (5): 347-52
71. West SG, Hinderliter AL, Wells EC, et al. Transdermal estrogen reduces vascular resistance and serum cholesterol in postmenopausal women. Am J Obstet Gynecol 2001 Apr; 184 (5): 926-33
72. Kushwaha RS, Lewis DS, Carey KD, et al. Effects of estrogen and progesterone on plasma lipoproteins and experimental atherosclerosis in the baboon (Papio sp.). Arterioscler Thromb 1991 Jan-Feb; 11 (1): 23-31
73. Parini P, Angelin B, Rudling M. Importance of estrogen receptors in hepatic LDL receptor regulation. Arterioscler Thromb Vasc Biol 1997; 17: 1800-5
74. Abbey M, Owen A, Suzakawa M, et al. Effects of menopause and hormone replacement therapy on plasma lipids, lipoproteins and LDL-receptor activity. Maturitas 1999; 33: 259-69
75. Homma Y, Homma K, Iizuka S, et al. A case of anorexia nervosa with severe hyperlipoproteinemia. Int J Eat Disord 2002 Jul; 32 (1): 121-4
76. Thong FSL, McLean C, Graham TE. Plasma leptin in female athletes: relationship with body fat, reproductive, nutritional, and endocrine factors. J Appl Physiol 2000; 88: 2037-44
77. Loucks AB, Laughlin GA, Mortola JF, et al. Hypothalamic-pituitary- thyroidal function in eumenorrheic and amenorrheic athletes. J Clin Endocrinol Metab 1992 Aug; 75 (2): 514-8
78. Laughlin GA, Dominguez CE, Yen SS. Nutritional and endocrine-metabolic aberrations in women with functional hypothalamic amenorrhea. J Clin Endocrinol Metab 1998 Jan; 83 (1): 25-32
79. Spieker LE, Sudano I, Hurlimann D, et al. High-density lipoprotein restores endothelial function in hypercholesterolemic men. Circulation 2002 Mar 26; 105 (12): 1399-402
80. Guetta V, Cannon RO. Cardiovascular effects of estrogen and lipid-lowering therapies in postmenopausal women. Circulation 1996; 93: 1928-37
81. Lamon-Fava S. High-density lipoproteins: effects of alcohol, estrogen, and phytoestrogens. Nutr Rev 2002 Jan; 60 (1): 1-7
82. Segrest JP, Li L, Anantharamaiah GM, et al. Structure and function of apolipoprotein A-I and high-density lipoprotein. Curr Opin Lipidol 2000 Apr; 11 (2): 105-15
83. Saku K, Ahmad M, Glas-Greenwalt P, et al. Activation of fibrinolysis by apolipoproteins of high density lipoproteins in man. Thromb Res 1985 Jul 1; 39 (1): 1-8
84. Ramet ME, Ramet M, Lu Q, et al. High-density lipoprotein increases the abundance of eNOS protein in human vascular endothelial cells by increasing its half-life. J Am Coll Cardiol 2003 Jun 18; 41 (12): 2288-97
85. Bonnefront-Rousselot D, Therond P, Beaudeux JL, et al. High density lipoprotein (HDL) and the oxidative hypothesis of atherosclerosis. Clin Chem Lab Med 1999; 37: 939-48
86. Bittner V. Lipoprotein abnormalities related to women's health. Am J Cardiol 2002 Oct 17; 90 (8A): 77i-84i
87. Silva PM. Estrogen and the vessel wall: effects on endothelium-dependent stimuli. In: Castro MN, Birkhauser M, Clarkson TB, et al., editors. Menopause and the heart. London: The Parthenon Publishing Group, 1999: 7-14
88. Suda Y, Ohta H, Makita K, et al. Influence of bilateral oophorectomy upon lipid metabolism. Maturitas 1998 Jun 3; 29 (2): 147-54
89. Zhang X, Jiao J, Bhavnani BR, et al. Regulation of human apolipoprotein A-1 gene expression by equine estrogens. J Lipid Res 2001; 42: 1789-800
90. Pickar JH, Thorneycroft I, Whitehead M. Effects of hormone replacement therapy on the endometrium and lipid parameters: a review of randomized clinical trials, 1985 to 1995. Am J Obstet Gynecol 1998; 178: 1087-99
91. Perrella S, Berco M, Cecutti A, et al. Potential role of the interaction between equine estrogens, low-density lipoprotein (LDL) and high-density lipoprotein (HDL) in the prevention of coronary heart and neurodegenerative diseases in postmenopausal women. Lipids Health Dis 2003 Jun 20; 2 (1): 4
92. Ulloa N, Arteaga E, Bustos P, et al. Sequential estrogen-progestin replacement therapy in healthy postmenopausal women: effects on cholesterol efflux capacity and key proteins regulating high-density lipoprotein levels. Metabolism 2002 Nov; 51 (11): 1410-7
93. Podl TR, Zmuda JM, Yurgalevitch SM, et al. Lipoprotein lipase activity and plasma triglyceride clearance are elevated in endurance-trained women. Metabolism 1994 Jul; 43 (7): 808-13
94. Williams PT. High-density lipoprotein cholesterol and other risk factors for coronary heart disease in female runners. N Engl J Med 1996; 334 (20): 1298-303
95. Zmuda JM, Yurgalevitch SM, Flynn MM, et al. Exercise training has little effect on HDL levels and metabolism in men with initially low HDL cholesterol. Atherosclerosis 1998 Mar; 137 (1): 215-21
96. Smorawinska A, Korman E, Rajewski A, et al. Thyroid function and lipid metabolism in patients with anorexia nervosa [in Polish]. Psychiatr Pol 2003 Jan-Feb; 37 (1): 39-46
97. Comuzzie AG, Blangero J, Mahaney MC, et al. Triiodothyronine exerts a major pleiotropic effect on reverse cholesterol transport phenotypes. Arterioscler Throrab Vasc Biol 1996 Feb; 16 (2): 289-93
98. Harber VJ, Petersen SR, Chilibeck PD. Thyroid hormone concentrations and muscle metabolism in amenorrheic and eumenorrheic athletes. Can J Appl Physiol 1998 Jun; 23 (3): 293-306
99. Rapp RJ. Hypertriglyceridemia: a review beyond low-density lipoprotein. Cardiol Rev 2002 May-Jun; 10 (3): 163-72
100. Gotto AM. Triglyceride as a risk factor for coronary artery disease. Am J Cardiol 1998; 82: 22Q-5Q
101. Frachart JC, Duriez P. HDL and triglyceride as therapeutic targets. Curr Opin Lipidol 2002 Dec; 13 (6): 605-16
102. Rendell M, Hulthen UL, Tornquist C, et al. Relationship between abdominal fat compartments and glucose and lipid metabolism in early postmenopausal women. J Clin Endocrinol Metab 2001; 86: 744-9
103. Walsh BW, Schiff I, Rosner B, et al. Effects of postmenopausal estrogen replacement on the concentrations and metabolism of plasma lipoproteins. N Engl J Med 1991 Oct 24; 325 (17): 1196-204
104. Lobo RA. Effects of hormonal replacement on lipids and lipoproteins in postmenopausal women. J Clin Endocrinol Metab 1991; 73: 925-30
105. Erberich LC, Alcantara VM, Picheth G, et al. Hormone replacement therapy in postmenopausal women and its effects on plasma lipid levels. Clin Chem Lab Med 2002 May; 40 (5); 446-51
106. Case T, Lemieux S, Kennedy SH, et al. Elevated plasma lipids in patients with binge eating disorders are found only in those who are anorexic. Int J Eat Disord 1999 Mar; 25 (2): 187-93
107. Durstine JL, Haskell WL. Effects of exercise training on plasma lipids and lipoproteins. Exerc Sport Sci Rev 1994; 22: 477-521
108. Brown RC, Cox CM. Effects of high fat versus high carbohydrate diets on plasma lipids and lipoproteins in endurance athletes. Med Sci Sports Exerc 1998 Dec; 30 (12): 1677-83
109. Volek JS, Sharman MJ, Gomez AL, et al. An isoenergetic very low carbohydrate diet improves serum HDL cholesterol and triacylglycerol concentrations, the total cholesterol to HDL cholesterol ratio and postprandial pipemic responses compared with a low fat diet in normal weight, normolipidemic women. J Nutr 2003 Sep; 133 (9): 2756-61
110. Dekkers JC, van Doornen LJP, Kemper HCG, et al. The role of antioxidant vitamins and enzymes in the prevention of exercise-induced muscle damage. Sports Med 1996; 24: 213-38
111. Sanchez-Quesada JL, Ortega H, Payes-Romero A, et al. LDL from aerobically-trained subjects shows higher resistance to oxidative modification than LDL from sedentary subjects. Atherosclerosis 1997 Jul 25; 132 (2): 207-13
112. Witztum JL, Steinberg D. Role of oxidized low density lipoprotein in atherogenesis. J Clin Invest 1991 Dec; 88 (6): 1785-92
113. Tangirala RK, Mol MJ, Steinberg D. Macrophage oxidative modification of low density lipoprotein occurs independently of its binding to the low density lipoprotein receptor. J Lipid Res 1996 Apr; 37 (4): 835-43
114. Akova B, Surmen-Gur E, Gur H, et al. Exercise-induced oxidative stress and muscle performance in healthy women: role of vitamin E supplementation and endogenous oestradiol. Eur J Appl Physiol 2001 Jan-Feb; 84 (1-2): 141-7
115. Stoks SJ. The role of free radicals in toxicity and disease. J Basic Clin Physiol Pharmacol 1995; 6: 205-28
116. Sikka SC. Relative impact of oxidative stress on male reproductive function. Curr Med Chem 2001 Jun; 8 (7): 851-62
117. Urso ML, Clarkson PM. Oxidative stress, exercise, and antioxidant supplementation. Toxicology 2003 Jul 15; 189 (1-2): 41-54
118. Finkel T, Holbrook NJ. Oxidants, oxidative stress and the biology of ageing. Nature 2000 Nov 9; 408 (6809): 239-47
119. Sen CK. Antioxidants in exercise nutrition. Sports Med 2001; 31 (13): 891-908
120. Kanaley JA, Ji LL. Antioxidant enzyme activity during prolonged exercise in amenorrheic and eumenorrheic athletes. Metabolism 1991 Jan; 40 (1): 88-92
121. Carmeli E, Coleman R, Reznick AZ. The biochemistry of aging muscle. Exp Gerontol 2002 Apr; 37 (4): 477-89
122. Sack MN, Rader DJ, Cannon III RO. Oestrogen and inhibition of oxidation of low-density lipoproteins in postmenopausal women. Lancet 1994; 343: 269-70
123. Tranquilli AL, Mazzanti L, Cugini AM, et al. Transdermal estradiol and medroxyprogesterone acetate in hormone replacement therapy are both antioxidants. Gynecol Endocrinol 1995 Jun; 9 (2): 137-41
124. Subbiah MT, Kessel B, Agrawal M, et al. Antioxidant potential of specific estrogens on lipid peroxidation. J Clin Endocrinol Metab 1993 Oct; 77 (4): 1095-7
125. McManus J, McEneny J, Young IS, et al. The effect of various estrogens and progestogens on the susceptibility of low density lipoproteins to oxidation in vitro. Maturitas 1996; 25: 125-31
126. Shwaery GT, Vita JA, Keaney Jr JF. Antioxidant protection of LDL by physiologic concentrations of estrogens is specific for 17-beta-estradiol. Atherosclerosis 1998 Jun; 138 (2): 255-62
127. Bureau I, Lapone F, Favier M, et al. No antioxidant effect of combined HRT on LDL oxidizability and oxidative stress biomarkers in treated post-menopausal women. J Am Coll Nutr 2002 Aug; 21 (4): 333-8
128. Lawler JM, Hu Z, Green JS, et al. Combination of estrogen replacement and exercise protects against HDL oxidation in post-menopausal women. Int J Sports Med 2002 Oct; 23 (7): 477-83
129. Ozden S, Dildar K, Kadir YH, et al. The effects of hormone replacement therapy on lipid peroxidation and antioxidant status. Maturitas 2001 Apr 20; 38 (2): 165-70
130. Ruiz-Larrea MB, Martin C, Martinez R, et al. Antioxidant activities of estrogens against aqueous and lipophilic radicals; differences between phenol and catechol estrogens. Chem Phys Lipids 2000; 105: 179-88
131. Bednarek-Tupikowska G, Bohdanowicz-Pawlak A, Bidzinska B, et al. Serum lipid peroxide levels and erythrocyte glutathione peroxidase and superoxide dismutase activity in premenopausal and postmenopausal women. Gynecol Endocrinol 2001; 15 (4): 298-303
132. Serviddio G, Loverro G, Vicino M, et al. Modulation of endometrial redox balance during the menstrual cycle: relation with sex hormones. J Clin Endocrinol Metab 2002 Jun; 87 (6): 2843-8
133. Clarkson PM, Thompson HS. Antioxidants: what role do they play in physical activity and health? Am J Clin Nutr 2000 Aug; 72 (2 Suppl.): 637S-46S
134. Packer L. Oxidants, antioxidant nutrients and the athlete. J Sports Sci 1997 Jun; 15 (3): 353-63
135. Clarkson PM. Micronutrients and exercise: anti-oxidants and minerals. J Sports Sci 1995 Summer; 13 Spec. no.: S11-24
136. O'Callaghan YC, Woods JA, O'Brien NM. Oxysterol-induced cell death in U937 and HepG2 cells at reduced and normal serum concentrations. Eur J Nutr 1999 Dec; 38 (6): 255-62
137. Palazzetti S, Richard MJ, Favier A, et al. Overloaded training increases exercise-induced oxidative stress and damage. Can J Appl Physiol 2003 Aug; 28 (4): 588-604
138. Sen CK. Oxidants and antioxidants in exercise. J Appl Physiol 1995; 79: 675-86
139. Vasankari T, Lehtonen-Veromaa M, Mottonen T, et al. Reduced mildly oxidized LDL in young female athletes. Atherosclerosis 2000 Aug; 151 (2): 399-405
140. Child RB, Wilkinson DM, Fallowfield JL, et al. Elevated serum antioxidant capacity and plasma malondialdehyde concentration in response to a simulated half-marathon run. Med Sci Sports Exerc 1998 Nov; 30 (11): 1603-7
141. Mastaloudis A, Leonard SW, Traber MG. Oxidative stress in athletes during extreme endurance exercise. Free Radic Biol Med 2001 Oct 1; 31 (7): 911-22
142. Tiidus PM. Radical species in inflammation and overtraining. Can J Physiol Pharmacol 1998; 76: 533-8
143. Lovlin R, Cottle W, Pyke I, et al. Are indices of free radical damage related to exercise intensity. Eur J Appl Physiol Occup Physiol 1987; 56 (3): 313-6
144. Ji LL. Antioxidants and oxidative stress in exercise. Proc Soc Exp Biol Med 1999 Dec; 222 (3): 283-92
145. Marzatico F, Pansarasa O, Bertorelli L, et al. Blood free radical antioxidant enzymes and lipid peroxides following long-distance and lactacidemic performances in highly trained aerobic and sprint athletes. J Sports Med Phys Fitness 1997 Dec; 37 (4): 235-3
146. Štvrtinová V, Ferenèík M, Hulín I, et al. Vascular endothelium as a connecting operator in the information transfer between the cardiovascular and immune systems [in Slovak]. Bratisl Lek Listy 1998; 99: 5-19
147. Bonetti PO, Bareness GW, Keelan PC, et al. Enhanced external counterpulsation improves endothelial function in patients with symptomatic coronary artery disease. J Am Coll Cardiol 2003 May 21; 41 (10): 1761-8
148. Arnal JF, Bayard F. Vasculoprotective effects of oestrogens. Clin Exp Pharmacol Physiol 2001; 28: 1032-4
149. Kinlay S, Ganz P. Relation between endothelial dysfunction and the acute coronary syndrome: implications for therapy. Am J Cardiol 2000 Oct; 86 (8 Suppl. 2): 10-3
150. Vallance P, Hingorani A. Endothelial nitric oxide in humans in health and disease. Int J Exp Pathol 1999 Dec; 80 (6): 291-303
151. Celermajer DS, Dollery C, Burch M, et al. Role of endothelium in the maintenance of low pulmonary vascular tone in normal children. Circulation 1994 May; 89 (5): 2041-4
152. Maeda S, Miyauchi T, Kakiyama T, et al. Effects of exercise training of 8 weeks and detraining on plasma levels of endothelium-derived factors, endothelin-1 and nitric oxide, in healthy young humans. Life Sci 2001 Jul 20; 69 (9): 1005-16
153. Moncada S, Higgs A. The L-arginine-nitric oxide pathway. N Engl J Med 1993; 329: 2002-12
154. Panza JA, Casino PR, Kilcoyne CM, et al. Role of endothelium-derived nitric oxide in the abnormal endothelium-dependent vascular relaxation of patients with essential hypertension. Circulation 1993 May; 87 (5): 1468-74
155. Casino PR, Crescence MK, Quyyumi AA, et al. The role of nitric oxide in endothelium-dependent vasodilation of hypercholesterolemic patients. Circulation 1993; 88: 2541-7
156. McVeigh GE, Brennan GM, Johnston GD, et al. Impaired endothelium- dependent and independent vasodilation in patients with type 2 (non-insulin-dependent) diabetes mellitus. Diabetologia 1992 Aug; 35 (8): 771-6
157. Hutchison S. Smoking as a risk factor for endothelial dysfunction. Can J Cardiol 1998 Jul; 14 Suppl. D: 20D-2D
158. Zeiher AM, Drexler H, Wollschlager H, et al. Endothelial dysfunction of the coronary microvasculature is associated with coronary blood flow regulation in patients with early atherosclerosis. Circulation 1991 Nov; 84 (5): 1984-92
159. Guetta V, Quyyumi AA, Prasad A, et al. The role of nitric oxide in coronary vascular effects of estrogen in postmenopausal women. Circulation 1997; 96: 2795-801
160. Ohmichi M, Kanda Y, Hisamoto K, et al. Rapid changes of flow-mediated dilatation after surgical menopause. Maturitas 2003 Feb 25; 44 (2): 125-31
161. Joyner MJ, Tschakovsky ME. Nitric oxide and physiologic vasodilation in human limbs: where do we go from here? Can J Appl Physiol 2003 Jun; 28 (3): 475-90
162. Koh KK. Effects of estrogen on the vascular wall: vasomotor function and inflammation. Cardiovasc Res 2002 Sep; 55 (4): 714-26
163. Gilligan DM, Badar DM, Panza JA, et al. Acute vascular effects of estrogen in postmenopausal women. Circulation 1994 Aug; 90 (2): 786-91
164. Gerhard M, Walsh BW, Tawakol A, et al. Estradiol therapy combined with progesterone and endothelium-dependent vasodilation in postmenopausal women. Circulation 1998 Sep 22; 98 (12): 1158-63
165. Sorensen KE, Dorup I, Hermann AP, et al. Combined hormone replacement therapy does not protect women against the age-related decline in endothelium-dependent vasomotor function. Circulation 1998 Apr 7; 97 (13): 1234-8
166. Rosselli M, Imthurn B, Keller PJ, et al. Circulating nitric oxide (nitrite/nitrate) levels in postmenopausal women substituted with 17β-estradiol and norethisterone acetate: a two-year follow-up study. Hypertension 1995; 25: 848-53
167. Webb CM, Ghatei MA, McNeill JG, et al. 17beta-estradiol decreases endothelin-1 levels in the coronary circulation of postmenopausal women with coronary artery disease. Circulation 2000; 102: 1617-22
168. Westendorp ICD, Bots ML, Grobbee DE, et al. Menopausal status and distensibility of the common carotid artery. Arterioscler Thromb 1999; 19: 713-7
169. Arora S, Veves A, Caballaro AE, et al. Estrogen improves endothelial function. J Vasc Surg 1998 Jun; 27 (6): 1141-6
170. Mihmanli I, Mihmanli V, Kantarci F, et al. The effect of an acute decrease in serum estrogen concentration on vessel walls: determination with color and pulsed Doppler ultrasound. Arch Gynecol Obstet 2003 Jan; 267 (3): 134-8
171. Chester A, Jiang C, Borland J, et al. Oestrogen relaxes human epicardial coronary arteries through non-endothelium dependent mechanisms. Coron Artery Dis 1995; 95 (6): 417-22
172. Yang AL, Tsai SJ, Jiang MJ, et al. Chronic exercise increases both inducible and endothelial nitric oxide synthase gene expression in endothelial cells of rat aorta. J Biomed Sci 2002 Mar-Apr; 9 (2): 149-55
173. Jungersten L, Edlund A, Petersson AS, et al. Plasma nitrate as an index of nitric oxide formation in man: analyses of kinetics and confounding factors. Clin Physiol 1996; 16: 369-79
174. Rodriguez-Plaza LG, Alfieri AB, Cubeddu LX. Urinary excretion of nitric oxide metabolites in runners, sedentary individuals and patients with coronary artery disease: effects of 42 km marathon, 15 km race and a cardiac rehabilitation program. J Cardiovasc Risk 1997 Oct-Dec; 4 (5-6): 367-72
175. Blumel JE, Castelo-Branco C, Leal T, et al. Effects of transdermal estrogens on endothelial function in postmenopausal women with coronary disease. Climacteric 2003 Mar; 6 (1): 38-44
176. Celermajer DS, Sorensen KE, Gooch VM, et al. Non-invasive detection of endothelial dysfunction in children and adults at risk of atherosclerosis. Lancet 1992 Nov; 340 (8828): 1111-5
177. Anderson TJ, Uehata A, Gerhard MD, et al. Close relation of endothelial function in the human coronary and peripheral circulations. J Am Coll Cardiol 1995 Nov 1; 26 (5): 1235-41
178. Hoch AZ, Jurva J, Staton M, et al. Is endothelial dysfunction that is associated with amenorrheic athletes reversible [abstract]? Med Sci Sports Exerc 2003; 35 (5): S12
179. Wellman GC, Brayden JE, Nelson MT. A proposed mechanism for the cardioprotective effect of oestrogen in women: enhanced endothelial nitric oxide release decreases coronary artery reactivity. Clin Exp Pharmacol Physiol 1996 Mar; 23 (3): 260-6
180. Chen Z, Yuhanna IS, Galcheva-Gargova Z, et al. Estrogen receptor alpha mediates the nongenomic activation of endothelial nitric oxide synthase by estrogen. J Clin Invest 1999 Feb; 103 (3): 401-6
181. Haynes MP, Russell KS, Bender JR. Molecular mechanisms of estrogen actions on the vasculature. J Nucl Cardiol 2000 Sep-Oct; 7 (5): 500-8
182. O'Donnell E, Rodgers CD, Goodman J, et al. Endothelial function in hypoestrogenic physically active women [abstract]. Can J Appl Physiol 2003; 28: S88
183. Galetta F, Ferdinando F, Prattichizzo F, et al. Heart rate variability and left ventricular diastolic function in anorexia nervosa. J Adolesc Health 2003; 32: 416-21
184. Clarkson P, Montgomery HE, Mullen MJ, et al. Exercise training enhances endothelial function in young men. J Am Coll Cardiol 1999 Apr; 33 (5): 1379-85
185. Kingwell BA, Jennings GL, Dart AM. Exercise and endothelial function. Circulation 2000 Nov 28; 102 (22): E179
186. Kingwell BA. Nitric oxide-mediated metabolic regulation during exercise: effects of training in health and cardiovascular disease. FASEB J 2000 Sep; 14 (12): 1685-96
187. Maxwell AJ, Schauble E, Bernstein D, et al. Limb blood flow during exercise is dependent on nitric oxide. Circulation 1998 Jul 28; 98 (4): 369-74
188. Sader MA, Celermajer DS. Endothelial function, vascular reactivity and gender differences in the cardiovascular system. Cardiovasc Res 2002 Feb 15; 53 (3): 597-604
189. Suzuki T, Nakamura Y, Moriya T, et al. Effects of steroid hormones on vascular functions. Microsc Res Tech 2003 Jan 1; 60 (1): 76-84
190. Venkov CD, Rankin AB, Vaughan DE. Identification of authentic estrogen receptor in cultured endothelial cells: a potential mechanism for steroid hormone regulation of endothelial function. Circulation 1996 Aug 15; 94 (4): 727-33
191. Karas RH, Patterson BL, Mendelsohn ME. Human vascular smooth muscle cells contain functional estrogen receptor. Circulation 1994 May; 89 (5): 1943-50
192. Zhu Y, Bian Z, Lu P, et al. Abnormal vascular function and hypertension in mice deficient in estrogen receptor beta. Science 2002 Jan 18; 295 (5554): 505-8
193. Alonso D, Radomski MW. The nitric oxide-endothelin-1 connection. Heart Fail Rev 2003 Jan; 8 (1): 107-15
194. Taddei S, Virdis A, Ghiadoni L, et al. Vascular effects of endothelin-1 in essential hypertension: relationship with cyclooxygenase-derived endothelium-dependent contracting factors and nitric oxide. J Cardiovasc Pharmacol 2000; 35 (4 Suppl. 2): S37-40
195. Best PJ, Berger PB, Miller VM, et al. The effect of estrogen replacement therapy on plasma nitric oxide and endothelin-1 levels in postmenopausal women. Ann Intern Med 1998: 128 (4): 285-8
196. Wingrove CS, Stevenson JC. 17 beta-Oestradiol inhibits stimulated endothelin release in human vascular endothelial cells. Eur J Endocrinol 1997 Aug; 137 (2): 205-8
197. Mathew V, Hasdai D, Lerman A. The role of endothelin in coronary atherosclerosis. Mayo Clin Proc 1996; 71: 769-77
198. Anwaar I, Rendell M, Gottsater A, et al. Hormone replacement therapy in healthy postmenopausal women: effects on intraplatelet cyclic guanosine monophosphate, plasma endothelin-1 and neopterin. J Intern Med 2000 Apr; 247 (4): 463-70
199. Haenggi W, Bersinger NA, Mueller MD, et al. Decrease of serum endothelin levels with postmenopausal hormone replacement therapy or tibolone. Gynecol Endocrinol 1999 Jun; 13 (3): 202-5
200. Jhund PS, Dawson N, Davie AP, et al. Attenuation of endothelin-1 induced vasoconstriction by 17beta estradiol is not sustained during long-term therapy in postmenopausal women with coronary heart disease. J Am Coll Cardiol 2001 Apr; 37 (5): 1367-73
201. Akishita M, Kozaki K, Eto M, et al. Estrogen attenuates endothelin-1 production by bovine endothelial cells via estrogen receptor. Biochem Biophys Res Commun 1998 Oct 9; 251 (1): 17-21
202. Dubey RK, Jackson EK, Keller PJ, et al. Estradiol metabolites inhibit endothelin synthesis by an estrogen receptor-independent mechanism. Hypertension 2001 Feb; 37 (2 Pt 2): 640-4
203. Polderman KH, Stehouwer CD, van Kamp GJ, et al. Modulation of plasma endothelin levels by the menstrual cycle. Metabolism 2000 May; 49 (5): 648-50
204. Maeda S, Tanabe T, Miyauchi T, et al. Aerobic exercise training reduces plasma endothelin-1 concentration in older women. J Appl Physiol 2003 Jul; 95 (1): 336-41
205. Mayer EL, Jacobsen DW, Robinson K. Homocysteine and coronary atherosclerosis. J Am Coll Cardiol 1996 Mar; 27 (3): 517-27
206. Dimitrova KR, DeGroot K, Myers AK, et al. Estrogen and homocysteine. Cardiovasc Res 2002 Feb 15; 53 (3): 577-88
207. Ozkan Y, Ozkan E, Simsek B. Plasma total homocysteine and cysteine levels as cardiovascular risk factors in coronary heart disease. Int J Cardiol 2002 Mar; 82 (3): 269-77
208. Warren CJ. Emergent cardiovascular risk factor; homocysteine. Prog Cardiovasc Nurs 2002 Winter; 17 (1): 35-41
209. Verhoef P, Kok FJ, Kruyssen DA, et al. Plasma total homocysteine, B vitamins, and risk of coronary atherosclerosis. Arterioscler Thromb Vasc Biol 1997; 17: 989-95
210. Dimitrova KR, DeGroot KW, Suyderhoud JP, et al. 17-beta estradiol preserves endothelial cell viability in an in vitro model of homocysteine-induced oxidative stress. J Cardiovasc Pharmacol 2002 Mar; 39 (3): 347-53
211. Tsai JC, Perrella MA, Yoshizumi M, et al. Promotion of vascular smooth muscle cell growth by homocysteine: a link to atherosclerosis. Proc Natl Acad Sci U S A 1994 Jul 5; 91 (14): 6369-73
212. Hajjar KA. Homocysteine-induced modulation of tissue plasminogen activator binding to its endothelial cell membrane receptor. J Clin Invest 1993; 91: 2873-9
213. Majors A, Ehrhart LA, Pezacka EH. Homocysteine as a risk factor for vascular disease: enhanced collagen production and accumulation by smooth muscle cells. Arterioscler Thromb Vasc Biol 1997; 17: 2074-81
214. McCully KS. Chemical pathology of homocysteine: I. Atherogenesis. Ann Clin Lab Sci 1993 Nov-Dec; 23 (6): 477-93
215. Kang SS, Wong PWK, Norusis M. Homocysteinemia due to folate deficiency. Metabolism 1987; 36: 458-62
216. Nygard O, Nordrehaug JE, Refsum H, et al. Plasma homocysteine levels and mortality in patients with coronary artery disease. N Engl J Med 1997 Jul; 337 (4): 230-6
217. Wouters MG, Moorrees MT, van der Mooren MJ, et al. Plasma homocysteine and menopausal status. Eur J Clin Invest 1995 Nov; 25 (11): 801-5
218. Walker MC, Smith GN, Perkins SL, et al. Changes in homocysteine levels during normal pregnancy. Am J Obstet Gynecol 1999 Mar; 180 (3 Pt 1): 660-4
219. Boers GHJ, Smals AGH, Trijbels JMF, et al. Unique efficiency of methionine metabolism in premenopausal women may protect against vascular disease in the reproductive years. J Clin Invest 1983; 72: 1971-6
220. Venkatraman JT, Pendergast DR. Effect of dietary intake on immune function in athletes. Sports Med 2002; 32 (5): 323-37
221. Hawley JA, Dennis SC, Lindsay FH, et al. Nutritional practices of athletes: are they sub-optimal? J Sports Sci 1995 Summer; 13 Spec. no.: S75-81
222. Kopp-Woodroffe SA, Manore MM, Dueck CA, et al. Energy and nutrient status of amenorrheic athletes participating in a diet and exercise training intervention program. Int J Sports Nutr 1999; 9: 70-88
223. Ubbink JB, Vermaak WJH, van der Merwe A, et al. Vitamin requirements for the treatment of hyperhomocysteinemia in humans. J Nutr 1994; 124: 1927-33
224. Moyano D, Vilaseca MA, Artuch R, et al. Plasma total-homocysteine in anorexia nervosa. Eur J Clin Nutr 1998 Mar; 52 (3): 172-5
225. Tallova J, Tomandl J, Bicikova M, et al. Changes of plasma total homocysteine levels during the menstrual cycle. Eur J Clin Invest 1999 Dec; 29 (12): 1041-4
226. Upchurch Jr GR, Welch GN, Fabian AJ, et al. Homocyst (e)ine decreases bioavailable nitric oxide by a mechanism involving glutathione peroxidase. J Biol Chem 1997; 272: 17012-7
227. Ross R. Atherosclerosis is an inflammatory disease. Am Heart J 1999 Nov; 138 (5 Pt 2): S419-20
228. Silvestri A, Gebara O, Vitale C, et al. Increased levels of C-reactive protein after oral hormone replacement therapy may not be related to an increased inflammatory response. Circulation 2003 Jul 1; 107 (25): 3165-9
229. Culley FJ, Bodman-Smith KB, Ferguson MA, et al. C-reactive protein binds to phosphorylated carbohydrates. Glycobiology 2000 Jan; 10 (1): 59-65
230. Koenig W, Sund M, Frohlich M, et al. C-Reactive protein, a sensitive marker of inflammation, predicts future risk of coronary heart disease in initially healthy middle-aged men: results from the MONICA (Monitoring Trends and Determinants in Cardiovascular Disease) Augsburg Cohort Study, 1984 to 1992. Circulation 1999 Jan; 99 (2): 237-42
231. Blake GJ, Ridker PM. C-reactive protein, subclinical atherosclerosis, and risk of cardiovascular events. Arterioscler Thromb Vasc Biol 2002 Oct 1; 22 (10): 1512-3
232. Ridker PM, Buring JE, Shin J, et al. Prospective study of C-reactive protein and risk of future cardiovascular events among apparently healthy women. Circulation 1998; 98 (8): 731-3
233. Pepys MB. The acute phase response and C-reactive protein. In: Weatherall DJ, Ledingham JGC, Warrell DA, editors. Oxford textbook of medicine. New York: Oxford University Press, 1996: 1527-33
234. Heilbronn LK, Noakes M, Clifton PM. Energy restriction and weight loss on very-low-fat diets reduce C-reactive protein concentrations in obese, healthy women. Arterioscler Thromb Vasc Biol 2001 Jun; 21 (6): 968-70
235. Pepys MB, Hirschfield GM. C-reactive protein: a critical update. J Clin Invest 2003 Jun; 111 (12): 1805-11
236. Fallen KE, Fallen SK, Boston T. The acute phase response and exercise: court and field sports. Br J Sports Med 2001 Jun; 35 (3): 170-3
237. Rosenson RS, Koenig W. Utility of inflammatory markers in the management of coronary artery disease. Am J Cardiol 2003 Jul 3; 92 (1A): 10i-8i
238. Cushman M, Legault C, Barrett-Connor E, et al. Effect of postmenopausal hormones on inflammation-sensitive proteins: the Postmenopausal Estrogen/Progestin Interventions (PEPI) study. Circulation 1999; 100: 717-22
239. Ridker PM, Hennekens CH, Rifai N, et al. Hormone replacement therapy and increased plasma concentration of C-reactive protein. Circulation 1999 Aug; 100 (7): 713-6
240. Oger E, Alhenc-Gelas M, Plu-Bureau G, et al. Association of circulating cellular adhesion molecules with menopausal status and hormone replacement therapy: time-dependent change in transdermal, but not oral estrogen users. Thromb Res 2001 Jan; 101 (2): 35-43
241. Mattusch F, Dufaux B, Heine O, et al. Reduction of the plasma concentration of C-reactive protein following nine months of endurance training. Int J Sports Med 2000 Jan; 21 (1): 21-4
242. Dufaux B, Order U, Geyer H, et al. C-reactive protein serum concentrations in well-trained athletes. Int J Sports Med 1984 Apr; 5 (2): 102-6
243. Akimoto T, Furudate M, Saitoh M, et al. Increased plasma concentrations of intercellular adhesion molecule-1 after strenuous exercise associated with muscle damage. Eur J Appl Physiol 2002 Jan; 86 (3): 185-90
244. Radomski M. Sports injuries [online]. Available from URL; http://www.canultimate.com/articles/Radomski.html [Accessed 2003 Aug 21]
245. MacIntyre DL, Reid WD, McKenzie DC. Delayed muscle soreness: the inflammatory response to muscle injury and its clinical implications. Sports Med 1995 Jul; 20 (1): 24-40
246. Tiidus PM. Estrogen and gender effects on muscle damage, inflammation, and oxidative stress. Can J Appl Physiol 2000 Aug; 25 (4): 274-87
247. Loucks AB, Horvath SM. Athletic amenorrhea: a review. Med Sci Sports Exerc 1985 Feb; 17 (1): 56-72
248. Taubes G. Cardiovascular disease: does inflammation cut to the heart of the matter? Science 2002; 296: 242-5
249. Yudkin JS, Stehouwer CDA, Emeis JJ, et al. C-reactive protein in healthy subjects: associations with obesity, insulin resistance, and endothelial dysfunction: a potential role for cytokines originating from adipose tissue? Arterioscler Thromb Vasc Biol 1999; 19: 972-8
250. Sites CK, Toth MJ, Cushman M, et al. Menopause-related differences in inflammation markers and their relationship to body fat distribution and insulin-stimulated glucose disposal. Fertil Steril 2002 Jan; 77 (1): 128-35
251. Bermudez EA, Rifai N, Buring J, et al. Interrelationships among circulating interleukin-6, C-reactive protein, and traditional cardiovascular risk factors in women. Arterioscler Thromb Vasc Biol 2002 Oct 1; 22 (10): 1668-73
252. Robson P. Elucidating the unexplained underperformance syndrome in endurance athletes: the interleukin-6 hypothesis. Sports Med 2003; 33 (10): 771-81
253. Davison S, Davis SR. New markers for cardiovascular disease risk in women: impact of endogenous estrogen status and exogenous postmenopausal hormone therapy. J Clin Endocrinol Metab 2003 Jun; 88 (6): 2470-8
254. Nova E, Samartin S, Gomez S, et al. The adaptive response of the immune system to the particular malnutrition of eating disorders. Eur J Clin Nutr 2002 Aug; 56 Suppl. 3: S34-7
255. Montera A, Lopez-Vareia S, Nova E, et al. The implication of the binomial nutrition-immunity on sportswomen's health. Eur J Clin Nutr 2002 Aug; 56 (3 Suppl.): S38-41
256. Beckvid Henriksson G, Schnell C, Linden Hirschberg A. Women endurance runners with menstrual dysfunction have prolonged interruption of training due to injury. Gynecol Obstet Invest 2000; 49 (1): 41-6
257. Pedersen BK, Steensberg A, Fischer C, et al. Searching for the exercise factor: is IL-6 a candidate? J Muscle Res Cell Motil 2003; 24 (2-3): 113-9
258. De Souza MJ, Maguire MS, Maresh CM, et al. Adrenal activation and the prolactin response to exercise in eumenorrheic and amenorrheic runners. J Appl Physiol 1991 Jun; 70 (6): 2378-87
259. Rome ES. Epidemiology of eating disorders. Obstet Gynecol Clin North Am 2003; 30 (2): 353-77